EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

ScandiDos AB (SDOS) fair value: what the stock is really worth

As of Oct 16, 2026: fair value of ScandiDos AB SEK 0.13, price SEK 0.60, upside -78.6%, quality 32 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · SE · ISIN SE0005768124

SA ScandiDos AB logo Thin data Oct 3, 2026

ScandiDos AB

SDOS · ST

Weakest SetupStrongly overvalued and low quality.

Our calculation puts a fair price 79% below what the stock costs today.

Low debt
Insider activity 40/100
Fair value kr 0.1275 · Strongly overvalued (−78.6%)
Quality 32/100
Weak Growth (revenue 5y −2.0 %/yr in SEK)
Loss-making · -16.8% net margin (TTM)
Negative free cash flow
Trails peers (3/10)
Narrow moat 15/100 · thin data
Thin data
⚠ Dilution
Watch ScandiDos AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 4.00 kr 0.5850 Fair Value kr 0.1275 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range kr 0.5850 – kr 4.00 · fair‑value band kr 0.0850 – kr 0.1615 · the kr 0.5950 price screens above the kr 0.1275 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.

Follow ScandiDos in your weekly email

Every Wednesday you see whether ScandiDos is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ScandiDos AB (publ), together with its subsidiaries, provides measurement phantoms and software solutions for the quality assurance and validation of dynamic and modulated treatments adopted in clinics in the United States, Europe, Asia, and internationally.

Show moreShow less

The company offers Delta4 products comprising Delta4 Phantom+, Delta4Phantom+MR, Delta4 HexaMotion, Delta4Insight, Delta4DVH Anatomy, Delta4 Machine QA, and Delta4 Statistics Module for the quality assurance in advanced radiation therapy techniques, such as VMAT, RapidArc, IMRT, and Tomotherapy.

It sells its products directly to consumers and through distributors. ScandiDos AB (publ) was founded in 2001 and is headquartered in Uppsala, Sweden.

Stock analysis

ScandiDos AB (SDOS) currently trades at kr 0.5950, while our model-based Fair Value estimate is kr 0.1275, 78.6% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: kr 0.0850 (bear) to kr 0.1615 (bull), the price of kr 0.5950 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

ScandiDos AB reported revenue of 54.2M SEK in FY2026 versus 57.7M SEK in FY2022, a compound −1.5%/yr. Reported net income was −3.4M SEK in FY2026.

Key figures

Market cap 43.1M SEK (≈ $4.4M) · P/S ratio 0.88 · EPS (TTM) kr −0.1200 · Net margin −6.3% · Return on equity −18.3% · Return on assets (EBIT) −12.4% · Operating margin −109% · Revenue (TTM) 48.9M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (low confidence).

What moves the price

The share trades about 50% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at −79%, SDOS screens richer than that median.

Fair Value models

Bear kr 0.0850 Fair Value kr 0.1275 Bull kr 0.1615
Price kr 0.5950 · Upside -78.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) kr 0.2900 kr 0.3900 kr 0.5800 54
All 1 models by family
Asset-Based
NCAV (Graham) kr 0.2900 kr 0.3900 kr 0.5800 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 12
How much profit the company makes from its sales and capital
Quality Growth 50
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 55
Debt, balance sheet and risk of trouble
Investment 91
Does it invest with discipline instead of growing at any price?
Low Volatility 66
How calm the share price moves, does not count
Momentum 6
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−10.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.0%
Start year 2021 (pandemic). Over 10 years: +4.9% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−0.6% (2021) → −5.0% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

SDOS screens overvalued: fair value 79% below the price. Compare with Abbott Laboratories, →

Compare ScandiDos AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 325 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside −78.6% · Bottom 25%
Profitability
Return on assets −5.2% · Below median
Net margin (12 months) −16.8% · Bottom 25%
Operating margin (12 months) −109.1% · Bottom 25%
Growth and dividend
Revenue growth −46.2% · Bottom 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.10× · Cheapest 25%
P/S (12 months) 0.09× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 7
FUTURE (revenue growth)0 · sector 35
PAST (return on equity)0 · sector 16
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 39

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $282.60 $310.86 +10% vs SDOS
Boston Scientific Corporation BSX $43.00 $47.30 +10% vs SDOS
DexCom, Inc DXCM $84.11 $92.52 +10% vs SDOS
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥166.00 ¥182.60 +10% vs SDOS
GE HealthCare Technologies Inc GEHC $65.74 $70.37 +7% vs SDOS
Edwards Lifesciences Corporation EW $85.78 $81.94 −4% vs SDOS
Siemens Healthineers AG SHL €38.26 €35.19 −8% vs SDOS
Abbott Laboratories, ABT $102.61 $74.79 −27% vs SDOS
Medtronic plc MDT $91.93 $65.61 −29% vs SDOS
Koninklijke Philips N.V PHIA €22.18 €15.23 −31% vs SDOS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ScandiDos AB · Fair Value
kr 0.1275 −79%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "ScandiDos AB Fair Value". https://www.fairvalue-calculator.com/stock/SDOS

Frequently asked questions

Is ScandiDos AB (SDOS) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of kr 0.1275 versus a price of kr 0.5950, about −79% upside (overvalued).
What is the fair value of SDOS?
Our model-based fair value for ScandiDos AB is kr 0.1275 (as of Oct 3, 2026), built from audited fundamentals. The current price: kr 0.5950.
What is the quality score of SDOS?
ScandiDos AB has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ScandiDos AB (SDOS)?
Our model-based price target is the fair value of kr 0.1275 (as of Oct 3, 2026) from 1 valuation models. Cautious scenario kr 0.0850, optimistic scenario kr 0.1615. It is a calculation from audited fundamentals, not an analyst target.
What is the ScandiDos AB stock forecast for 2026?
Our models put fair value at kr 0.1275, about −79% upside versus a price of kr 0.5950 (overvalued). Cautious scenario kr 0.0850, optimistic scenario kr 0.1615. The calculation is refreshed regularly with new filings.
What is the revenue of ScandiDos AB (SDOS)?
ScandiDos AB reported trailing-twelve-month revenue of about 48.9M SEK (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of ScandiDos AB (SDOS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ScandiDos AB it is kr 0.1275 per share (as of Oct 3, 2026), against a price of kr 0.5950. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is ScandiDos AB stock overvalued or undervalued in 2026?
As of Oct 3, 2026, SDOS trades above its calculated fair value: price kr 0.5950, fair value kr 0.1275, a gap of about −79% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SDOS?
No. The price is what the market pays today (kr 0.5950); the fair value is what the company's own numbers justify (kr 0.1275). For ScandiDos AB the two are kr 0.4675 per share apart. That gap is exactly why we show both numbers side by side.
How much is ScandiDos AB worth?
The market values ScandiDos AB at about 43.1M SEK (market capitalisation, as of Oct 3, 2026). Per share that is kr 0.5950; our models calculate a fair value of kr 0.1275 per share.
What do the bullish and bearish scenarios say about SDOS?
Our models span a range for ScandiDos AB: cautious scenario kr 0.0850, base kr 0.1275, optimistic kr 0.1615 per share (as of Oct 3, 2026, price kr 0.5950). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ScandiDos AB (SDOS)?
Balance-sheet figures for ScandiDos AB (as of Oct 3, 2026): return on equity −18.3%. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is SDOS from its 52-week high?
ScandiDos AB trades at kr 0.5950, about 50% below its 52-week high of kr 1.20 and 2% above the low of kr 0.5850 (as of Oct 16, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.1275 is for.
Which stocks are comparable to ScandiDos AB?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ScandiDos AB stock attractive at the current price?
The data as of Oct 3, 2026: price kr 0.5950, calculated fair value kr 0.1275 (−79%), Quality Score 32/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SDOS calculated?
We run ScandiDos AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.1275, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.4 % above its aggregate fair value. ScandiDos AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ScandiDos AB (SDOS)?
The closing price on Oct 16, 2026 was kr 0.5950. Our model-based fair value is kr 0.1275, about −79% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ScandiDos AB right now?
The price sits above even our optimistic bull case (kr 0.1615). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 0.0850 to kr 0.1615) leaves room in how you read the outcome.

Key figures of ScandiDos AB

How large is the market capitalisation of ScandiDos AB (SDOS)?
The market capitalisation of ScandiDos AB is 43.1M SEK (≈ $4.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ScandiDos AB (SDOS)?
The price-to-sales ratio of ScandiDos AB is 0.88 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ScandiDos AB (SDOS)?
Earnings per share at ScandiDos AB are kr −0.1200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of ScandiDos AB (SDOS)?
The net margin of ScandiDos AB is −6.3% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ScandiDos AB (SDOS)?
The return on equity (ROE) of ScandiDos AB is −18.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ScandiDos AB (SDOS)?
On an EBIT basis the return on assets of ScandiDos AB is −12.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ScandiDos AB (SDOS)?
The operating margin of ScandiDos AB is −109% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ScandiDos AB (SDOS)?
Revenue at ScandiDos AB is growing −46.2% versus a year earlier (3y avg −4.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ScandiDos AB (SDOS)?
Earnings per share at ScandiDos AB are growing −39.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does ScandiDos AB (SDOS) generate?
The free cash flow of ScandiDos AB is −6.8M SEK (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does ScandiDos AB (SDOS) hold?
ScandiDos AB holds more cash than debt, 4.4M SEK net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch ScandiDos AB in the live analysis

One click puts ScandiDos AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.